Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

LEVODOPA

Unique Identifier:SPE02300205
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:186.101 g/mol
X log p:5.387  (online calculus)
Lipinksi Failures1
TPSA17.07
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:5
Rotatable Bond Count:3
Canonical Smiles:NC(Cc1ccc(O)c(O)c1)C(O)=O
Class:amino acid
Source:Vicia faba seedlings, Sarothamnus spp, & other palnts
Therapeutics:antiparkinsonian
Generic_name:Levodopa
Chemical_iupac_name:2-amino-3-(3,4-dihydroxyphenyl)-propanoic acid
Drug_type:Approved Drug
Pharmgkb_id:PA450213
Kegg_compound_id:C00355
Drugbank_id:APRD00309
Melting_point:276-278 oC
H2o_solubility:5000 mg/L
Logp:-2.244
Isoelectric_point:2.32
Cas_registry_number:59-92-7
Mass_spectrum:http://webbook.nist.gov/cgi/cbook.cgi?Spec=C59927&Index=0&Type=Mass&Large=on
Drug_category:Dopamine Agents; Antiparkinson Agents; Antidyskinetics; ATC:N04BA01; ATC:N04BA04
Indication:For the treatment of idiopathic Parkinson-s disease (Paralysis Agitans),
postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to
the nervous system by carbon monoxide intoxication, and manganese intoxication.
Pharmacology:Levodopa (L-dopa) is used to replace dopamine lost in Parkinson-s disease because
dopamine itself cannot cross the blood-brain barrier where its precursor can.
However, L-DOPA is converted to dopamine in the periphery as well as in the CNS, so
it is administered with a peripheral DDC (dopamine decarboxylase) inhibitor such as
carbidopa, without which 90% is metabolised in the gut wall, and with a COMT
inhibitor if possible; this prevents about a 5% loss. The form given therapeutically
is therefore a prodrug which avoids decarboxylation in the stomach and periphery,
can cross the blood-brain barrier, and once in the brain is converted to the
neurotransmitter dopamine by the enzyme aromatic-L-amino-acid decarboxylase.
Mechanism_of_action:Striatal dopamine levels in symptomatic Parkinson-s disease are decreased by 60 to
80%, striatal dopaminergic neurotransmission may be enhanced by exogenous
supplementation of dopamine through administration of dopamine-s precursor,
levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier
and is decarboxylated to dopamine. This newly formed dopamine then is available to
stimulate dopaminergic receptors, thus compensating for the depleted supply of
endogenous dopamine.
Organisms_affected:Humans and other mammals

Found: 205 nonactive as graph: single | with analogs [1] << Back 31 32 33 34 35 36 37 38 39 40  Next >> [205]
Species: 4932
Condition: CIN2
Replicates: 2
Raw OD Value: r im 0.7536±0.0253851
Normalized OD Score: sc h 0.9868±0.0126889
Z-Score: -0.7395±0.702521
p-Value: 0.512256
Z-Factor: -5.42453
Fitness Defect: 0.6689
Bioactivity Statement: Nonactive
Experimental Conditions
Library:Spectrum
Plate Number and Position:21|H11
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:27.30 Celcius
Date:2006-02-14 YYYY-MM-DD
Plate CH Control (+):0.0393±0.00136
Plate DMSO Control (-):0.7314±0.04966
Plate Z-Factor:0.7672
png
ps
pdf

DBLink | Rows returned: 18<< Back 1 2 3
6919173 (2S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-2-methyl-propanoate
6927358 (2R)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-2-methyl-propanoate
6971033 (2S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)propanoate
6989908 (2R)-2-azaniumyl-3-(3,4-dihydroxyphenyl)propanoate
12002502 (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid hydrochloride
16042129 (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid chloride

internal high similarity DBLink | Rows returned: 5
RJC 01671 0.9474
LOPAC 00283 1.0000
LOPAC 00613 1.0000
LOPAC 01063 1.0000
SPE01500403 1.0000

active | Cluster 12980 | Additional Members: 10 | Rows returned: 2
SPE01502206 0.55
LOPAC 01089 0.55

Service provided by the Mike Tyers Laboratory